A Delaware jury ruled in favor of Gilead Sciences, finding that the company’s HIV prevention medicines Truvada and Descovy do not infringe on U.S. government patents and that the patents themselves are invalid in the first place. The company also announced it was acquiring private San Diego biotech XinThera.